21 November 2017
News and Views
Links and Services
This week's issue of the New England Journal of Medicine examines patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response.
Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments ar
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors